Lessons from the Past: Opportunities to Improve Childhood Cancer Survivor Care Through Outcomes Investigations of Historical Therapeutic Approaches for Pediatric Hematological Malignancies

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2011 Nov 1

PMID 22038641

Citations 77

Authors

Melissa M Hudson

Joseph P Neglia

William G Woods

John T Sandlund

Ching-Hon Pui

Larry E Kun

Leslie L Robison

Daniel M Green

Affiliations

Soon will be listed here.

Abstract

Investigations of long-term outcomes have been instrumental in designing safer and more effective contemporary therapies for pediatric hematological malignancies. Despite the significant therapeutic changes that have occurred over the last five decades, therapy modifications largely represent refinements of treatment protocols using agents and modalities that have been available for more than 30 years. This review summarizes major trends in the evolution of treatment of pediatric hematological malignancies since 1960 to support the relevance of the study of late effects of historical therapeutic approaches to the design and evaluation of contemporary treatment protocols and the follow-up of present-day survivors.

Citing Articles

Risk-Stratified Radiotherapy in Pediatric Cancer.

Upadhyay R, Paulino A Cancers (Basel). 2024; 16(20).

PMID: 39456624 PMC: 11506666. DOI: 10.3390/cancers16203530.

Yamanishi A, Determan D, Kuo D J Pediatr Pharmacol Ther. 2024; 29(1):53-60.

PMID: 38332966 PMC: 10849689. DOI: 10.5863/1551-6776-29.1.53.

Kinetics and Role of Pancreatic Stone Protein and Midregional Proadrenomedullin as Predictors of Sepsis and Bacteremia in Children with Hematological Malignancies.

Antari V, Skoura L, Hatzipantelis E, Tsinopoulou V, Papakonstantinou K, Protonotariou E Mediterr J Hematol Infect Dis. 2023; 15(1):e2023065.

PMID: 38028393 PMC: 10631712. DOI: 10.4084/MJHID.2023.065.

Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.

Wilson C, Bjornard K, Partin R, Kadan-Lottick N, Nathan P, Oeffinger K J Cancer Surviv. 2023; .

PMID: 37938431 PMC: 11076414. DOI: 10.1007/s11764-023-01483-1.

Cardiovascular Risk Factor Disparities in Adult Survivors of Childhood Cancer Compared With the General Population.

Noyd D, Liu Q, Yasui Y, Chow E, Bhatia S, Nathan P JACC CardioOncol. 2023; 5(4):489-500.

PMID: 37614575 PMC: 10443116. DOI: 10.1016/j.jaccao.2023.01.011.

References

Balduzzi A, Gooley T, Anasetti C, Sanders J, Martin P, Petersdorf E . Unrelated donor marrow transplantation in children. Blood. 1995; 86(8):3247-56. View

Schwartz C, Constine L, Villaluna D, London W, Hutchison R, Sposto R . A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009; 114(10):2051-9. PMC: 2744567. DOI: 10.1182/blood-2008-10-184143. View

Donaldson S, Link M . Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987; 5(5):742-9. DOI: 10.1200/JCO.1987.5.5.742. View

Temming P, Qureshi A, Hardt J, Leiper A, Levitt G, Ancliff P . Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer. 2011; 56(4):625-30. DOI: 10.1002/pbc.22908. View

Matloub Y, Bostrom B, Hunger S, Stork L, Angiolillo A, Sather H . Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(2):243-51. PMC: 3138679. DOI: 10.1182/blood-2010-12-322909. View

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

Henslee-Downey P, Abhyankar S, Parrish R, Pati A, Godder K, Neglia W . Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997; 89(10):3864-72. View

Kaplan H . On the natural history, treatment, and prognosis of Hodgkin's disease. Harvey Lect. 1968; 64:215-59. View

AUR R, HUSTU H, Simone J, Pratt C, Pinkel D . Therapy of localized and regional lymphosarcoma of childhood. Cancer. 1971; 27(6):1328-31. DOI: 10.1002/1097-0142(197106)27:6<1328::aid-cncr2820270608>3.0.co;2-a. View

10.

Lange B, Smith F, Feusner J, Barnard D, Dinndorf P, Feig S . Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2007; 111(3):1044-53. PMC: 2214754. DOI: 10.1182/blood-2007-04-084293. View

11.

Kersey J . Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997; 90(11):4243-51. View

12.

Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S . Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995; 13(2):359-72. DOI: 10.1200/JCO.1995.13.2.359. View

13.

Wells R, Woods W, Buckley J, Odom L, Benjamin D, Bernstein I . Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol. 1994; 12(11):2367-77. DOI: 10.1200/JCO.1994.12.11.2367. View

14.

Reiter A, Schrappe M, Ludwig W, Lampert F, Harbott J, Henze G . Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992; 80(10):2471-8. View

15.

Philip T, Pinkerton R, Biron P, Ladjadj Y, Bouffet E, Souillet G . Effective multiagent chemotherapy in children with advanced B-cell lymphoma: who remains the high risk patient?. Br J Haematol. 1987; 65(2):159-64. DOI: 10.1111/j.1365-2141.1987.tb02258.x. View

16.

Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, Weinstein H . Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer. 2009; 53(6):1005-10. PMC: 3508725. DOI: 10.1002/pbc.22165. View

17.

CAPIZZI R, Poole M, Cooper M, Richards 2nd F, Stuart J, Jackson Jr D . Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood. 1984; 63(3):694-700. View

18.

Bostrom B, Sensel M, Sather H, Gaynon P, La M, Johnston K . Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003; 101(10):3809-17. DOI: 10.1182/blood-2002-08-2454. View

19.

TUBERGEN D, Gilchrist G, OBrien R, Coccia P, Sather H, Waskerwitz M . Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol. 1993; 11(3):527-37. DOI: 10.1200/JCO.1993.11.3.527. View

20.

Woods W, Kobrinsky N, Buckley J, Lee J, Sanders J, Neudorf S . Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87(12):4979-89. View